SG10201701057SA - Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione - Google Patents
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dioneInfo
- Publication number
- SG10201701057SA SG10201701057SA SG10201701057SA SG10201701057SA SG10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA
- Authority
- SG
- Singapore
- Prior art keywords
- oxoisoindolin
- morpholinomethyl
- dione
- piperidine
- oxy
- Prior art date
Links
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681447P | 2012-08-09 | 2012-08-09 | |
| US201261722727P | 2012-11-05 | 2012-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201701057SA true SG10201701057SA (en) | 2017-03-30 |
Family
ID=49004013
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701057SA SG10201701057SA (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| SG10202108516PA SG10202108516PA (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| SG11201500998QA SG11201500998QA (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202108516PA SG10202108516PA (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| SG11201500998QA SG11201500998QA (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20140045843A1 (OSRAM) |
| EP (2) | EP3949968A1 (OSRAM) |
| JP (2) | JP6347782B2 (OSRAM) |
| KR (3) | KR102146848B1 (OSRAM) |
| CN (4) | CN114366746A (OSRAM) |
| AU (1) | AU2013299627C1 (OSRAM) |
| BR (1) | BR112015002285B1 (OSRAM) |
| CA (1) | CA2881116C (OSRAM) |
| CY (1) | CY1124622T1 (OSRAM) |
| DK (1) | DK2882442T3 (OSRAM) |
| EA (1) | EA029485B1 (OSRAM) |
| ES (1) | ES2881220T3 (OSRAM) |
| HR (1) | HRP20211243T1 (OSRAM) |
| HU (1) | HUE056127T2 (OSRAM) |
| IL (3) | IL288506B2 (OSRAM) |
| IN (1) | IN2015DN00886A (OSRAM) |
| LT (1) | LT2882442T (OSRAM) |
| MX (1) | MX367869B (OSRAM) |
| NI (1) | NI201500012A (OSRAM) |
| NZ (1) | NZ628078A (OSRAM) |
| PH (1) | PH12015500212A1 (OSRAM) |
| PL (1) | PL2882442T3 (OSRAM) |
| PT (1) | PT2882442T (OSRAM) |
| RS (1) | RS62201B1 (OSRAM) |
| SG (3) | SG10201701057SA (OSRAM) |
| SI (1) | SI2882442T1 (OSRAM) |
| SM (1) | SMT202100457T1 (OSRAM) |
| TW (2) | TWI653977B (OSRAM) |
| UA (1) | UA116544C2 (OSRAM) |
| WO (1) | WO2014025960A1 (OSRAM) |
| ZA (1) | ZA201500564B (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| RS56232B1 (sr) | 2010-02-11 | 2017-11-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene |
| DK2691384T3 (en) | 2011-03-28 | 2017-01-16 | Mei Pharma Inc | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE |
| MX358517B (es) | 2012-06-29 | 2018-08-24 | Celgene Corp | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| WO2014039960A1 (en) * | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| MX386337B (es) | 2013-12-06 | 2025-03-18 | Celgene Corp | Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células b grandes, mieloma múltiple, y cánceres mieloides. |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| JP2017538104A (ja) * | 2014-10-07 | 2017-12-21 | セルジーン コーポレイション | 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 |
| AU2016326499A1 (en) * | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| WO2018144445A1 (en) * | 2017-01-31 | 2018-08-09 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| CN110799245B (zh) * | 2017-05-16 | 2022-08-09 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| MX2019013862A (es) | 2017-05-23 | 2020-01-20 | Mei Pharma Inc | Terapia de combinacion. |
| CA3068591A1 (en) * | 2017-06-30 | 2019-01-03 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide |
| SG11202000143PA (en) * | 2017-07-10 | 2020-02-27 | Celgene Corp | Antiproliferative compounds and methods of use thereof |
| EP3668507A4 (en) | 2017-08-14 | 2021-05-12 | MEI Pharma, Inc. | Combination therapy |
| WO2019060693A1 (en) * | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019084434A1 (en) | 2017-10-26 | 2019-05-02 | National University Of Singapore | NEW APPROACH FOR UNIVERSAL MONITORING OF MINIMUM RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US20210196725A1 (en) * | 2018-08-14 | 2021-07-01 | Mei Pharma, Inc. | Treatment of relapsed follicular lymphoma |
| WO2020048547A1 (zh) * | 2018-09-07 | 2020-03-12 | 南京明德新药研发有限公司 | 三环并呋喃取代哌啶二酮类化合物 |
| US11529339B2 (en) * | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| US12263190B2 (en) | 2018-11-08 | 2025-04-01 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| MX2021012216A (es) | 2019-04-05 | 2022-01-24 | Kymera Therapeutics Inc | Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos. |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| CN115671295B (zh) * | 2019-10-21 | 2025-10-28 | 新基公司 | 包含化合物的药物组合物及其使用方法 |
| BR112022007548A2 (pt) | 2019-11-07 | 2022-07-12 | Juno Therapeutics Inc | Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona |
| EP4069245A1 (en) * | 2019-12-02 | 2022-10-12 | Celgene Corporation | Therapy for the treatment of cancer |
| WO2021133920A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| IL299293A (en) * | 2020-06-25 | 2023-02-01 | Celgene Corp | Cancer treatment methods with combined treatments |
| MX2023003114A (es) | 2020-09-23 | 2023-03-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon. |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| MX2023009527A (es) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| AR125798A1 (es) | 2021-05-07 | 2023-08-16 | Kymera Therapeutics Inc | Degradadores cdk2 y usos de los mismos |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| TW202532072A (zh) | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| WO2006055689A2 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| CN103641814A (zh) * | 2007-03-20 | 2014-03-19 | 细胞基因公司 | 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法 |
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| RS56232B1 (sr) * | 2010-02-11 | 2017-11-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| JP6118273B2 (ja) * | 2011-03-11 | 2017-04-19 | セルジーン コーポレイション | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
-
2013
- 2013-08-08 EA EA201590345A patent/EA029485B1/ru not_active IP Right Cessation
- 2013-08-08 RS RS20210904A patent/RS62201B1/sr unknown
- 2013-08-08 EP EP21177385.8A patent/EP3949968A1/en active Pending
- 2013-08-08 DK DK13751007.9T patent/DK2882442T3/da active
- 2013-08-08 CN CN202110936758.6A patent/CN114366746A/zh active Pending
- 2013-08-08 US US13/962,776 patent/US20140045843A1/en not_active Abandoned
- 2013-08-08 SG SG10201701057SA patent/SG10201701057SA/en unknown
- 2013-08-08 CN CN201380052496.0A patent/CN104837491A/zh active Pending
- 2013-08-08 HU HUE13751007A patent/HUE056127T2/hu unknown
- 2013-08-08 IL IL288506A patent/IL288506B2/en unknown
- 2013-08-08 ES ES13751007T patent/ES2881220T3/es active Active
- 2013-08-08 PT PT137510079T patent/PT2882442T/pt unknown
- 2013-08-08 AU AU2013299627A patent/AU2013299627C1/en active Active
- 2013-08-08 KR KR1020157006019A patent/KR102146848B1/ko active Active
- 2013-08-08 TW TW102128576A patent/TWI653977B/zh active
- 2013-08-08 CN CN201711401933.1A patent/CN108245518B/zh active Active
- 2013-08-08 SM SM20210457T patent/SMT202100457T1/it unknown
- 2013-08-08 TW TW107117959A patent/TWI723266B/zh active
- 2013-08-08 KR KR1020207023283A patent/KR102266510B1/ko active Active
- 2013-08-08 MX MX2015001775A patent/MX367869B/es active IP Right Grant
- 2013-08-08 CN CN202110938460.9A patent/CN114344307A/zh active Pending
- 2013-08-08 EP EP13751007.9A patent/EP2882442B1/en active Active
- 2013-08-08 JP JP2015526690A patent/JP6347782B2/ja active Active
- 2013-08-08 SG SG10202108516PA patent/SG10202108516PA/en unknown
- 2013-08-08 UA UAA201501971A patent/UA116544C2/uk unknown
- 2013-08-08 NZ NZ628078A patent/NZ628078A/en unknown
- 2013-08-08 WO PCT/US2013/054055 patent/WO2014025960A1/en not_active Ceased
- 2013-08-08 IN IN886DEN2015 patent/IN2015DN00886A/en unknown
- 2013-08-08 HR HRP20211243TT patent/HRP20211243T1/hr unknown
- 2013-08-08 CA CA2881116A patent/CA2881116C/en active Active
- 2013-08-08 PL PL13751007T patent/PL2882442T3/pl unknown
- 2013-08-08 SG SG11201500998QA patent/SG11201500998QA/en unknown
- 2013-08-08 KR KR1020217018115A patent/KR102414005B1/ko active Active
- 2013-08-08 LT LTEPPCT/US2013/054055T patent/LT2882442T/lt unknown
- 2013-08-08 SI SI201331908T patent/SI2882442T1/sl unknown
- 2013-08-08 BR BR112015002285-5A patent/BR112015002285B1/pt active IP Right Grant
-
2015
- 2015-01-26 ZA ZA2015/00564A patent/ZA201500564B/en unknown
- 2015-01-29 IL IL237013A patent/IL237013B/en active IP Right Grant
- 2015-01-30 PH PH12015500212A patent/PH12015500212A1/en unknown
- 2015-02-06 NI NI201500012A patent/NI201500012A/es unknown
-
2016
- 2016-05-13 US US15/154,838 patent/US20160256468A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017168A patent/JP2018100276A/ja not_active Withdrawn
-
2019
- 2019-08-01 US US16/529,233 patent/US20190388429A1/en not_active Abandoned
-
2020
- 2020-07-27 IL IL276319A patent/IL276319B/en unknown
-
2021
- 2021-07-16 CY CY20211100645T patent/CY1124622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288506B1 (en) | Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione | |
| ZA201306305B (en) | Methods of treating cancer using 3-(5-amino-2-methyl-4h-quinazolin-3-yl)-piperidine-2,6-dione | |
| IL244494A0 (en) | Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-6,2-dione | |
| IL236922A0 (en) | Salts and solid forms of (4))-4)-3-(s-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and compounds containing them and methods of their use | |
| IL236925A0 (en) | Processes for the preparation of (s)-3-4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and acceptable pharmaceutical forms thereof | |
| IL225520A0 (en) | History of 4-(methylaminophenoxy)pyridin-3-yl-benzamide for cancer treatment |